Estrella Immunopharma announced on February 21, 2025, the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. This trial is evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy.
Following a review of safety and efficacy data by the Data and Safety Monitoring Board (DSMB), approval was granted to initiate the second dose cohort. This next cohort will administer a higher dose of 5M receptor-positive T cells per kilogram of body weight of EB103.
This progression indicates that the initial dose level was well-tolerated and allows the company to explore potentially more effective dose concentrations. Advancing to a higher dose cohort is a key step in the clinical development process for EB103.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.